Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT06830044 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG: Milsaperidone
DRUG: Placebo

Sponsor

Vanda Pharmaceuticals